Anti-SMYD3 Antibody

This polyclonal antibody targets SMYD3, a SET- and MYND-domain-containing histone lysine methyltransferase that catalyzes trimethylation of histone H3 at lysine 4 and has been linked to transcriptional activation of oncogenic gene programs. Raised in rabbit and supplied as an unconjugated reagent, it is validated for western blot and immunofluorescence on human samples and is widely used to profile SMYD3 expression in hepatocellular carcinoma, colorectal, and breast cancer research models.

The reagent is provided as 100 µl of polyclonal serum, allowing multiple membrane blots or immunofluorescence runs from a single vial, and the unconjugated format gives researchers flexibility to pair it with their own HRP-conjugated or fluorophore-labeled secondary antibodies. SMYD3 overexpression correlates with poor prognosis in several solid tumor types, making reliable detection of the protein in cell lysates and fixed tissue sections a recurring need in cancer biology laboratories studying chromatin methylation, transcription factor recruitment, and the mechanistic links between histone modification and cell proliferation.

Distributed by Antibodies.com, this rabbit polyclonal reagent has been used in studies of ERBB2/HER2-driven breast cancer signaling, where SMYD3 was identified as a downstream effector contributing to proliferative and invasive phenotypes. Researchers performing siRNA or CRISPR knockdowns of SMYD3, characterizing small-molecule methyltransferase inhibitors, or mapping SMYD3 interactomes by co-immunoprecipitation use this antibody to confirm endogenous protein levels before and after perturbation. Refrigerated storage preserves polyclonal activity across extended experimental campaigns.